lymphoma

[Proceedings of the National Academy of Sciences of the United States of America] Researchers examined the immune cell profile of eight cell suspension samples of Lymphocyte-rich classic Hodgkin lymphoma (LR-CHL) in comparison to 20 samples of the mixed cellularity and nodular sclerosis subtypes of CHL.

[Stem Cell Research & Therapy] Investigators highlight the preclinical and clinical efforts made for addressing the drawbacks and also review additional potent stratagems that could improve CAR-T therapy in T cell malignancies.

[Cancer Cell] Researchers implemented EcoTyper, a machine-learning framework integrating transcriptome deconvolution and single-cell RNA sequencing, to characterize clinically relevant diffuse large B cell lymphoma cell states and ecosystems.

[Blood] Researchers identified adult diffuse large B-cell lymphoma (DLBCL) patients who received either an auto-hematopoietic cell transplant or CAR-T treatment with axicabtagene ciloleucelwhile in a partial remission by CT or PET scan.

[Journal of the National Cancer Institute] The authors recruited 114 patients with B cell malignancies, comprising 77 acute lymphoblastic leukemia and 37 non-Hodgkin lymphoma patients, who were treated with CART19 cells.

[Leukemia] Hodgkin lymphoma patients showed a decreased CD4 T-cell fraction, a higher percentage of effector-memory T cells and higher expression of activation markers at baseline.